CD8A and neoplasm: Because this is a heterogeneous population of cells, some of which have antitumor activity but some of which could be potentially immunosuppressive or cause toxicity, an effective biomarker that could specifically identify the repertoire of tumor-reactive and neoantigen-specific CD8+ T lymphocytes would be highly advantageous for enhancing clinical efficacy and safety (28).